Steven R. Sarkisian, Jr., MD - VISCO™360 versus SLT Glaucoma Trial

 Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA to                                       

Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA to Initiate the VISCO™360 versus SLT Glaucoma Trial Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA to                                        

Study will evaluate the safety and effectiveness of an ab interno procedure for patients with primary open angle glaucoma who do not have co-existing cataracts - the majority of the glaucoma patient population

Although this study is not yet enrolling at DMEI, this technology is already available for select patients at our institute.  Dr. Steven Sarkisian was the first surgeon in the country to perform this technique to lower eye pressure. Because the technique is reasonably safe, this FDA study is to help get an indication for using this device even earlier in the disease process.

MENLO PARK, Calif., July 26, 2016 /PRNewswire/ -- Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company announced today that it has received full IDE approval from the FDA to initiate the world's first clinical trial comparing ab interno canaloplasty with Selective Laser Trabeculoplasty (SLT). The VISCO™360 versus SLT Glaucoma Trial is a multi-center, prospective, randomized, controlled clinical evaluation that will study the safety and effectiveness of the Sight Sciences VISCO™360 Viscosurgical System in canaloplasty versus SLT in the reduction of intraocular pressure (IOP) in primary open angle glaucoma.

The VISCO™360 Viscosurgical System* is a fully integrated, single-handed, single-use device that combines a custom access cannula, a soft and flexible microcatheter with an atraumatic tip, an internal infusion pump and viscoelastic reservoir, and a control wheel that advances and retracts the microcatheter. 

Canaloplasty involves the circumferential catheterization and transluminal viscodilation of Schlemm's canal for the lowering of IOP in patients suffering from glaucoma. The procedure has been around for a decade using an ab externo approach. 

Dr. Steven Sarkisian, Professor of Ophthalmology at the Dean McGee Eye Institute at the University of Oklahoma and a principal investigator in the VISCO™360 Study explained, "I have performed hundreds of ab externo canaloplasties over the years with excellent results. I am excited to participate in the VISCO™360 study to characterize the safety and effectiveness of ab interno canaloplasty for patients with primary open angle glaucoma who do not need a combined procedure with cataract surgery. I believe that glaucoma specialists, comprehensive ophthalmologists, and any anterior segment surgeons will find this familiar ab interno approach to canaloplasty extremely useful for the care of their mild to moderate glaucoma patients and I look forward to participating in this important pivotal study". 

"We are extremely excited to begin this pivotal clinical trial investigating the use of our VISCO™360 device for this specific indication. We believe there is a huge unmet need for an effective ab interno glaucoma procedure that is not performed in conjunction with cataract removal and we look forward to working with all of our clinical partners in the execution of this large, robust FDA clinical study," stated Paul Badawi, Co-Founder and CEO of Sight Sciences.

Glaucoma is the world's leading cause of irreversible blindness and affects approximately 80 million people worldwide. Often associated with abnormally high IOP, glaucoma is characterized by progressive vision loss due to irreversible optic nerve damage. It is estimated that 20% of people with glaucoma do have co-existing cataracts while 80% of people with glaucoma do not have co-existing cataracts making a stand-alone surgical option like VISCO™360 an important part of an ophthalmologist's armamentarium.

About Sight Sciences: Sight Sciences is a medical device company dedicated to the development of technology-driven solutions that address the underlying physiology of ophthalmic disease. The company operates two business lines: surgical and non-surgical devices. Its surgical product portfolio consists of the TRAB™360 and VISCO™360 surgical devices. Its non-surgical product portfolio consists of technologies in the advanced stages of development for evaporative dry eye. For more information, visit

*The VISCO™360 device is available in the United States as a manual surgical tool but is investigational in the United States for the specific indication of IOP reduction in adult, pseudophakic patients with primary open angle glaucoma.

To view the original version on PR Newswire, visit:

 Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA toSOURCE  Sight Sciences, Inc.

10 comments (Add your own)

1. HollyMup wrote:
Деньги теперь не проблема. Заработать от 5000 руб в день легко на сайте -

Wed, April 25, 2018 @ 1:44 PM

2. RobertErrom wrote:
Go to this site and test new online games!

Mon, May 14, 2018 @ 6:57 PM

3. Danielhep wrote:
[url=]бесплатное порно[/url]

Wed, June 6, 2018 @ 12:30 AM

4. Francesca wrote:
Hi admin. It was hard to find this site in google.
It's not even in top 10. You should focus on strong links from high authority websites in your
niche. I know of a very effective free method to get strong backlinks and instant traffic.
The best thing about this method is that you start getting traffic right away.
For more details search in google for; masitsu's tricks

Sun, August 26, 2018 @ 12:31 PM

5. Roseanna wrote:
Hello,Neat post. There is a ρroblem tоgether with yoսr site in internet
explorer, mіght check tһis? IΕ nonetһeless is the market chief аnd
a big portion of folks will leave out yoᥙr wonderful writing ⅾue tο tһis problem.

Sun, September 30, 2018 @ 3:48 PM

6. Octavia wrote:
I enjoy wwhat ʏou guys tend to Ƅе up too. This kind of clever ԝork and exposure!
Keeр up thе excellent works guys I'vе added you guys to my blogroll.

Mon, October 1, 2018 @ 7:06 AM

7. Dalene wrote:
I'm impressed, I have to admit. Rarely do I encounter a blog that's equally educative
annd engaging, and let me tell you, you have hit the nail on the head.
The problem is something that not enouggh people are speaking intelligently
about. I am very happy I found thius during my hunt for something concerning this.

Sat, October 6, 2018 @ 5:57 PM

8. Antje wrote:
This post gives clear idea in favor of the new viewers of blogging,
that in fact how to do blogging.

Sun, October 28, 2018 @ 8:06 AM

9. Dani wrote:
I'm now not certain the place you're getting your information, however good topic.
I needs to spemd some time studying more or understanding more.Thank you
for wonderful information I was in search of tthis
info for my mission.

Wed, October 31, 2018 @ 10:28 PM

10. Tosha wrote:
Hi, its nice article about mediaa print, we all be aware of
media is a impressive source of facts.

Mon, November 12, 2018 @ 4:07 PM

Add a New Comment


Comment Guidelines: No HTML is allowed. Off-topic or inappropriate comments will be edited or deleted. Thanks.

Website by myheartcreative. Managed by Webvis CMS